Influencia de polimorfismos genéticos y niveles plasmáticos de adipocinas y eicosanoides en la supervivencia cardiovascular y del injerto en el trasplante renal

Zusammenfassung

Kidney transplantation is considered the treatment of choice in patients with end-stage renal disease. It is regulated by the immune system through the control of local and systemic inflammation. In a world in which inflammation is necessary for survival, its control is a complex medical challenge that prompts us to investigate inflammatory mediators and the development of therapies adapted to the physiology and pathophysiology of different processes. These inflammatory mediators include leptin, adiponectin, and EETs (epoxyeicosatrienoic acids). Leptin and adiponectin are adipokines secreted by adipose tissue, an organ that has gained relevance in recent years because of its participation in numerous physiological processes. These adipokines are related to EETs, metabolites derived from arachidonic acid, which have a relevant role in the immune system and cardiovascular risk. In the last decades, it has been shown that the patient’s genetic background may be key for the outcome of numerous diseases and therapeutic procedures. However, in the renal transplant setting, this concept has not been developed to date. Because of this, we present herein three research articles where we demonstrate the association between the presence of genetic variants that determine the synthesis of adipokynes and EETs and their actions with renal transplant outcomes.